SG11201906681PA - N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer - Google Patents
N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancerInfo
- Publication number
- SG11201906681PA SG11201906681PA SG11201906681PA SG11201906681PA SG11201906681PA SG 11201906681P A SG11201906681P A SG 11201906681PA SG 11201906681P A SG11201906681P A SG 11201906681PA SG 11201906681P A SG11201906681P A SG 11201906681PA SG 11201906681P A SG11201906681P A SG 11201906681PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cyclopropylmethyl
- pyrazol
- pyridin
- cyclohexane
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- XREIADPMSAUOHY-UHFFFAOYSA-N 4-N-[4-[5-(cyclopropylmethyl)-1-methylpyrazol-4-yl]pyridin-2-yl]cyclohexane-1,4-diamine Chemical class C1(CC1)CC1=C(C=NN1C)C1=CC(=NC=C1)NC1CCC(CC1)N XREIADPMSAUOHY-UHFFFAOYSA-N 0.000 title abstract 2
- 102000008122 Casein Kinase I Human genes 0.000 abstract 3
- 108010049812 Casein Kinase I Proteins 0.000 abstract 3
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 abstract 3
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- FNFMQIWXTYFRKA-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical class NC1[CH]CC(N)CC1 FNFMQIWXTYFRKA-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453192P | 2017-02-01 | 2017-02-01 | |
| PCT/IL2018/050100 WO2018142393A1 (en) | 2017-02-01 | 2018-01-30 | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906681PA true SG11201906681PA (en) | 2019-08-27 |
Family
ID=61198874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906681PA SG11201906681PA (en) | 2017-02-01 | 2018-01-30 | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11072599B2 (https=) |
| EP (1) | EP3577108B1 (https=) |
| JP (1) | JP7142646B2 (https=) |
| KR (1) | KR20190115017A (https=) |
| CN (1) | CN110475771B (https=) |
| AU (1) | AU2018215809B2 (https=) |
| CA (1) | CA3052247A1 (https=) |
| ES (1) | ES2902885T3 (https=) |
| IL (1) | IL268128B2 (https=) |
| MX (1) | MX394556B (https=) |
| NZ (1) | NZ755447A (https=) |
| RU (1) | RU2761457C2 (https=) |
| SG (1) | SG11201906681PA (https=) |
| TW (1) | TW201837027A (https=) |
| WO (1) | WO2018142393A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX384172B (es) * | 2015-08-04 | 2025-03-14 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivados de pirazol pirimidina y sus usos. |
| WO2019155468A1 (en) * | 2018-02-08 | 2019-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| WO2021000957A1 (zh) * | 2019-07-04 | 2021-01-07 | 北京国鸿生物医药科技有限公司 | 一种杂环化合物、其药物组合物及用途 |
| KR20230069169A (ko) * | 2020-09-17 | 2023-05-18 | 얀센 파마슈티카 엔.브이. | 카제인 키나제 1 델타 조절제 |
| US20240239774A1 (en) * | 2021-04-28 | 2024-07-18 | Cornell University | Soluble adenylyl cyclase (sac) inhibitors and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007129195A2 (en) * | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体 |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| EP2776432B1 (en) | 2011-11-04 | 2017-03-29 | Jasco Pharmaceuticals LLC | Aminopyrimidine kinase inhibitors |
| BR112016006319A2 (pt) | 2013-09-27 | 2017-08-01 | Nimbus Iris Inc | inibidores de irak e usos dos mesmos |
| US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CA2964982C (en) * | 2014-11-20 | 2022-07-05 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
| CN107847480B (zh) * | 2015-03-23 | 2021-06-25 | 墨尔本大学 | 呼吸性疾病的治疗 |
| MX384172B (es) | 2015-08-04 | 2025-03-14 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Derivados de pirazol pirimidina y sus usos. |
-
2018
- 2018-01-30 TW TW107103255A patent/TW201837027A/zh unknown
- 2018-01-30 CA CA3052247A patent/CA3052247A1/en active Pending
- 2018-01-30 JP JP2019561389A patent/JP7142646B2/ja active Active
- 2018-01-30 EP EP18705024.0A patent/EP3577108B1/en active Active
- 2018-01-30 US US16/482,199 patent/US11072599B2/en active Active
- 2018-01-30 SG SG11201906681PA patent/SG11201906681PA/en unknown
- 2018-01-30 NZ NZ755447A patent/NZ755447A/en unknown
- 2018-01-30 CN CN201880022829.8A patent/CN110475771B/zh not_active Expired - Fee Related
- 2018-01-30 KR KR1020197025024A patent/KR20190115017A/ko not_active Ceased
- 2018-01-30 WO PCT/IL2018/050100 patent/WO2018142393A1/en not_active Ceased
- 2018-01-30 IL IL268128A patent/IL268128B2/en unknown
- 2018-01-30 AU AU2018215809A patent/AU2018215809B2/en not_active Ceased
- 2018-01-30 RU RU2019127038A patent/RU2761457C2/ru active
- 2018-01-30 ES ES18705024T patent/ES2902885T3/es active Active
- 2018-01-30 MX MX2019009083A patent/MX394556B/es unknown
-
2021
- 2021-07-26 US US17/384,922 patent/US11999721B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019127038A (ru) | 2021-03-02 |
| EP3577108A1 (en) | 2019-12-11 |
| NZ755447A (en) | 2023-05-26 |
| MX394556B (es) | 2025-03-24 |
| US20200354340A1 (en) | 2020-11-12 |
| IL268128B (en) | 2022-11-01 |
| US11072599B2 (en) | 2021-07-27 |
| JP7142646B2 (ja) | 2022-09-27 |
| CA3052247A1 (en) | 2018-08-09 |
| RU2761457C2 (ru) | 2021-12-08 |
| CN110475771A (zh) | 2019-11-19 |
| ES2902885T3 (es) | 2022-03-30 |
| JP2020505468A (ja) | 2020-02-20 |
| US11999721B2 (en) | 2024-06-04 |
| WO2018142393A1 (en) | 2018-08-09 |
| KR20190115017A (ko) | 2019-10-10 |
| AU2018215809A1 (en) | 2019-08-15 |
| TW201837027A (zh) | 2018-10-16 |
| IL268128A (en) | 2019-09-26 |
| IL268128B2 (en) | 2023-03-01 |
| RU2019127038A3 (https=) | 2021-03-17 |
| AU2018215809B2 (en) | 2021-12-23 |
| CN110475771B (zh) | 2022-09-02 |
| MX2019009083A (es) | 2019-09-10 |
| ES2902885T8 (es) | 2022-04-06 |
| EP3577108B1 (en) | 2021-10-20 |
| US20220017493A1 (en) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201906681PA (en) | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201900883UA (en) | Combination treatment for hematological cancers | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201909305PA (en) | Cold slurry containment | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| SG11201807596YA (en) | Gitr antibodies, methods, and uses | |
| SG11201902567WA (en) | Expec glycoconjugate vaccine formulations | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor |